This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Immunoglobulin, Diagnosis, Evaluation, and Key Learnings Patient Registry (IDEaL™) (IDEaL)

This study is currently recruiting participants.
See Contacts and Locations
Verified May 2017 by Coram Clinical Trials
Information provided by (Responsible Party):
Coram Clinical Trials Identifier:
First received: April 21, 2010
Last updated: May 12, 2017
Last verified: May 2017

The IDEaL registry is a cooperative, observational registry focused on immunoglobulin use in the U.S. The registry is a deliberate and purposeful assembly of clinical and humanistic knowledge that is intended to act as a longitudinal database, tracking outcomes of routine clinical practice.

The central goal of the registry is to provide a mechanism that allows for a better understanding of how immunoglobulin therapy is being used in a real-world clinical setting. The data gathered will help the industry gain a better understanding surrounding the therapeutic value of immunoglobulin therapy and subsequently improve practices, reduce medical costs, and ultimately improve the clinical outcomes for the patients receiving immunoglobulin therapy

IVIg or SCIg Therapy in the Home or at Alternate Site

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Immunoglobulin, Diagnosis, Evaluation, and Key Learnings Patient Registry (IDEaL™)

Further study details as provided by Coram Clinical Trials:

Primary Outcome Measures:
  • Disease by geographic region (and/or Investigative Site), age, therapeutic indication (immunologic/neurologic) [ Time Frame: Baseline ]
  • Infection incidence by route, dose, and age [ Time Frame: every 6 months ]

Secondary Outcome Measures:
  • Dosing information by disease type, Investigative Site, and therapeutic indication [ Time Frame: Estimated for baseline and 1 year ]
  • Adverse events and serious adverse events by disease type and relation to Ig therapy [ Time Frame: Estimated for baseline and 1 year ]
  • IVIg vs SCIg by disease type and geographic region (and/or investigative site) [ Time Frame: Baseline ]
  • Current state of disease by number of Ig doses received and overall [ Time Frame: Estimated for 1 year ]
  • Payor type by investigator site [ Time Frame: Estimated for baseline and 1 year ]
  • Insurance reimbursement issues [ Time Frame: Estimated for baseline and 1 year ]
  • Concomitant medication use by disease type and therapeutic indication [ Time Frame: Estimated for baseline and 1 year ]

Estimated Enrollment: 400
Study Start Date: August 2010
Estimated Study Completion Date: August 2025
Estimated Primary Completion Date: August 2020 (Final data collection date for primary outcome measure)
IVIg and SCIg therapy

Detailed Description:

The registry's goal is to significantly contribute to the medical understanding of Ig therapy and to improve the quality of care for patients receiving Ig therapy in the United States through active publication of registry findings and disease management approaches.

The IDEaL program represents a unique and powerful method for the collection of:

Patient Level / Humanistic Data / Quality of Life Physician Level / Practice Patterns Clinical Data / Therapeutic Outcomes Reimbursement / Impact on Treatment / Policy Decisions


Accelerating innovation Producing faster knowledge gains Improving awareness of patient outcomes and disease burden Providing a clearer understanding of therapy impact on patients' quality of life.

The objectives of the Registry are:

to enhance the understanding of the variability, progression, and natural history of disease requiring Ig therapy with the ultimate goal of better guiding and assessing therapeutic intervention; to provide the Ig medical community with recommendations for monitoring patients and to provide reports on patient outcomes to help optimize patient care; and to serve as an active knowledge base that can provide population-management information, which can be used to generate patient-management and practice-management tools; and


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
The IDEaL Registry program will collect data representative of patients receiving Ig therapy (IVIg and SCIg) in a homecare setting and/or through Coram's ambulatory infusion suites.

Inclusion Criteria:

  • Signed informed consent
  • Any age, disease, or gender requiring Ig therapy
  • Agree to the use of Coram's infusion services after entry into IDEaL Registry
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01109810

Contact: L. Allyson Checkley, PhD 303.672.8888
Contact: Loretta Kristofek, RN 321-206-3969

United States, Colorado
Coram Clinical Trials Recruiting
Denver, Colorado, United States, 80202
Contact: L. Allyson Checkley, PhD    303-672-8888   
Contact: Loretta Kristofek, RN    321.206.3969   
Principal Investigator: Luqman Seidu, MD         
Sponsors and Collaborators
Coram Clinical Trials
Principal Investigator: Luqman Seidu, MD Unaffilated
  More Information

Responsible Party: Coram Clinical Trials Identifier: NCT01109810     History of Changes
Other Study ID Numbers: CT-10-02
Study First Received: April 21, 2010
Last Updated: May 12, 2017

Additional relevant MeSH terms:
Immunologic Factors
Physiological Effects of Drugs processed this record on July 26, 2017